arrow
R

Riccardo Bomben

centro di riferimento oncologico di aviano (cro) irccs
H指数:38
被引数:4,274

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial

分子生物标志物作为套细胞淋巴瘤预后的关键决定因素:FIL V-RBAC试验结果

2026-07-280
OA
Clonal hematopoiesis dynamics influences long-term outcomes of follicular lymphoma: Results from FIL FOLL12 trial

克隆性造血动态影响滤泡性淋巴瘤的长期结局:FIL FOLL12试验结果

2026-05-200
OAAI
Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia

免疫球蛋白同种型内多样化测量的结果细化了慢性淋巴细胞白血病中IGHV突变状态的临床影响。

Leukemia
IF13.4
2025-06-180
OAAI
Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement
LEUKEMIA
IF13.4
2024-12-170
OAAI
Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

V-Rbac背景下微小残留病评估,一项Fondazione Italiana Linfomi (FIL)风险定制II期临床试验

BLOOD
IF23.1
2024-11-050
PRE
A comprehensive luminal breast cancer patient-derived xenografts (PDX) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4/6 inhibitors
2024-10-250
OA
The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands
LEUKEMIA
IF13.4
2024-08-141
OAAI
CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experience
2024-07-151
OAAI
Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia
LEUKEMIA
IF13.4
2024-06-241
OAAI
Capturing tumor heterogeneity to personalize therapy in young patients with hormone receptor positive breast cancer
2024-03-220
PRE
NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia
LEUKEMIA
IF13.4
2024-03-154
OAAI
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort

Ibrutinib作为80岁以上慢性淋巴细胞白血病患者的一线治疗: 回顾性现实生活中的多中心意大利队列

2024-01-242
OAAI
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia
2023-04-170
PRE
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
LEUKEMIA
IF13.4
2023-02-1813
OAAI